These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 38916894)

  • 1. Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment: A Secondary Analysis of a Randomized Clinical Trial.
    Jensen SBK; Sørensen V; Sandsdal RM; Lehmann EW; Lundgren JR; Juhl CR; Janus C; Ternhamar T; Stallknecht BM; Holst JJ; Jørgensen NR; Jensen JB; Madsbad S; Torekov SS
    JAMA Netw Open; 2024 Jun; 7(6):e2416775. PubMed ID: 38916894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sperm count is increased by diet-induced weight loss and maintained by exercise or GLP-1 analogue treatment: a randomized controlled trial.
    Andersen E; Juhl CR; Kjøller ET; Lundgren JR; Janus C; Dehestani Y; Saupstad M; Ingerslev LR; Duun OM; Jensen SBK; Holst JJ; Stallknecht BM; Madsbad S; Torekov SS; Barrès R
    Hum Reprod; 2022 Jun; 37(7):1414-1422. PubMed ID: 35580859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery: The BARI-OPTIMISE Randomized Clinical Trial.
    Mok J; Adeleke MO; Brown A; Magee CG; Firman C; Makahamadze C; Jassil FC; Marvasti P; Carnemolla A; Devalia K; Fakih N; Elkalaawy M; Pucci A; Jenkinson A; Adamo M; Omar RZ; Batterham RL; Makaronidis J
    JAMA Surg; 2023 Oct; 158(10):1003-1011. PubMed ID: 37494014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial.
    Sandsdal RM; Juhl CR; Jensen SBK; Lundgren JR; Janus C; Blond MB; Rosenkilde M; Bogh AF; Gliemann L; Jensen JB; Antoniades C; Stallknecht BM; Holst JJ; Madsbad S; Torekov SS
    Cardiovasc Diabetol; 2023 Feb; 22(1):41. PubMed ID: 36841762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.
    Lundgren JR; Janus C; Jensen SBK; Juhl CR; Olsen LM; Christensen RM; Svane MS; Bandholm T; Bojsen-Møller KN; Blond MB; Jensen JB; Stallknecht BM; Holst JJ; Madsbad S; Torekov SS
    N Engl J Med; 2021 May; 384(18):1719-1730. PubMed ID: 33951361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protocol for a randomised controlled trial of the combined effects of the GLP-1 receptor agonist liraglutide and exercise on maintenance of weight loss and health after a very low-calorie diet.
    Jensen SBK; Lundgren JR; Janus C; Juhl CR; Olsen LM; Rosenkilde M; Holst JJ; Stallknecht BM; Madsbad S; Torekov SS
    BMJ Open; 2019 Nov; 9(11):e031431. PubMed ID: 31678947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes.
    Mensberg P; Nyby S; Jørgensen PG; Storgaard H; Jensen MT; Sivertsen J; Holst JJ; Kiens B; Richter EA; Knop FK; Vilsbøll T
    Diabetes Obes Metab; 2017 Feb; 19(2):172-180. PubMed ID: 27717126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial.
    Larsen JR; Vedtofte L; Jakobsen MSL; Jespersen HR; Jakobsen MI; Svensson CK; Koyuncu K; Schjerning O; Oturai PS; Kjaer A; Nielsen J; Holst JJ; Ekstrøm CT; Correll CU; Vilsbøll T; Fink-Jensen A
    JAMA Psychiatry; 2017 Jul; 74(7):719-728. PubMed ID: 28601891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
    Rubino DM; Greenway FL; Khalid U; O'Neil PM; Rosenstock J; Sørrig R; Wadden TA; Wizert A; Garvey WT;
    JAMA; 2022 Jan; 327(2):138-150. PubMed ID: 35015037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial.
    Jensen SBK; Blond MB; Sandsdal RM; Olsen LM; Juhl CR; Lundgren JR; Janus C; Stallknecht BM; Holst JJ; Madsbad S; Torekov SS
    EClinicalMedicine; 2024 Mar; 69():102475. PubMed ID: 38544798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss.
    Iepsen EW; Lundgren J; Dirksen C; Jensen JE; Pedersen O; Hansen T; Madsbad S; Holst JJ; Torekov SS
    Int J Obes (Lond); 2015 May; 39(5):834-41. PubMed ID: 25287751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women.
    Iepsen EW; Lundgren JR; Hartmann B; Pedersen O; Hansen T; Jørgensen NR; Jensen JE; Holst JJ; Madsbad S; Torekov SS
    J Clin Endocrinol Metab; 2015 Aug; 100(8):2909-17. PubMed ID: 26043228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
    Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
    Davies MJ; Bergenstal R; Bode B; Kushner RF; Lewin A; Skjøth TV; Andreasen AH; Jensen CB; DeFronzo RA;
    JAMA; 2015 Aug; 314(7):687-99. PubMed ID: 26284720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
    O'Neil PM; Birkenfeld AL; McGowan B; Mosenzon O; Pedersen SD; Wharton S; Carson CG; Jepsen CH; Kabisch M; Wilding JPH
    Lancet; 2018 Aug; 392(10148):637-649. PubMed ID: 30122305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploratory analysis of eating- and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment.
    Jensen SBK; Janus C; Lundgren JR; Juhl CR; Sandsdal RM; Olsen LM; Andresen A; Borg SA; Jacobsen IC; Finlayson G; Stallknecht BM; Holst JJ; Madsbad S; Torekov SS
    Nat Commun; 2022 Aug; 13(1):4770. PubMed ID: 35970829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
    le Roux CW; Astrup A; Fujioka K; Greenway F; Lau DCW; Van Gaal L; Ortiz RV; Wilding JPH; Skjøth TV; Manning LS; Pi-Sunyer X;
    Lancet; 2017 Apr; 389(10077):1399-1409. PubMed ID: 28237263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes.
    Silver HJ; Olson D; Mayfield D; Wright P; Nian H; Mashayekhi M; Koethe JR; Niswender KD; Luther JM; Brown NJ
    Diabetes Obes Metab; 2023 Aug; 25(8):2340-2350. PubMed ID: 37188932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Liraglutide on Arterial Inflammation Assessed as [
    Ripa RS; Zobel EH; von Scholten BJ; Jensen JK; Binderup T; Diaz LJ; Curovic VR; Hansen TW; Rossing P; Kjaer A
    Circ Cardiovasc Imaging; 2021 Jul; 14(7):e012174. PubMed ID: 34187185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.